The Medical Letter on Drugs and Therapeutics
Oritavancin (Orbactiv) for Skin and Skin Structure Infections
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved oritavancin (Orbactiv – The Medicines Company), a long-acting lipoglycopeptide antibiotic given as a single intravenous (IV) dose, for treatment of acute bacterial skin and skin structure infections caused by susceptible gram-positive bacteria in adults. It is the third lipoglycopeptide antibiotic to be marketed in the US; telavancin (Vibativ) and dalbavancin (Dalvance) were approved earlier.1,2

STANDARD TREATMENT – Purulent skin and soft-tissue infections are now caused predominantly by methicillin-resistant Staphylococcus aureus (MRSA) in many parts of the US. Patients hospitalized for complicated skin and soft-tissue infections suspected to be caused by MRSA are usually treated empirically with IV vancomycin. Some alternatives are listed in Table 3. For less serious MRSA infections, incision and ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Oritavancin (Orbactiv) for Skin and Skin Structure Infections
Article code: 1459c
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian